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Increased risk of low birth weight 
in women with placental malaria 
associated with P. falciparum 
VAR2CSA clade
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Mwayiwawo Madanitsa4,5, Carole Khairallah5, Linda Kalilani-Phiri4, Victor Mwapasa4, Achille 
Massougbodji6, Nadine Fievet7,8, Jeffery A. Bailey2,9, Feiko O. ter Kuile5, Philippe Deloron  7,8, 
Stephanie M. Engel1, Steve M. Taylor1,10, Jonathan J. Juliano1,3,11, Nicaise Tuikue Ndam7,8 & 
Steven R. Meshnick1
Pregnancy associated malaria (PAM) causes adverse pregnancy and birth outcomes owing to 
Plasmodium falciparum accumulation in the placenta. Placental accumulation is mediated by P. 
falciparum protein VAR2CSA, a leading PAM-specific vaccine target. The extent of its antigen diversity 
and impact on clinical outcomes remain poorly understood. Through amplicon deep-sequencing 
placental malaria samples from women in Malawi and Benin, we assessed sequence diversity of 
VAR2CSA’s ID1-DBL2x region, containing putative vaccine targets and estimated associations of 
specific clades with adverse birth outcomes. Overall, var2csa diversity was high and haplotypes 
subdivided into five clades, the largest two defined by homology to parasites strains, 3D7 or FCR3. 
Across both cohorts, compared to women infected with only FCR3-like variants, women infected with 
only 3D7-like variants delivered infants with lower birthweight (difference: −267.99 g; 95% Confidence 
Interval [CI]: −466.43 g,−69.55 g) and higher odds of low birthweight (<2500 g) (Odds Ratio [OR] 5.41; 
95% CI:0.99,29.52) and small-for-gestational-age (OR: 3.65; 95% CI: 1.01,13.38). In two distinct malaria-
endemic African settings, parasites harboring 3D7-like variants of VAR2CSA were associated with worse 
birth outcomes, supporting differential effects of infection with specific parasite strains. The immense 
diversity coupled with differential clinical effects of this diversity suggest that an effective VAR2CSA-
based vaccine may require multivalent activity.
Pregnant women are at increased risk of Plasmodium falciparum malaria infection and its adverse outcomes. 
Globally, an estimated 125 million pregnant women are at risk of malaria with 56 million of them living in regions 
with stable malaria transmission1–3. In these areas, pregnancy associated malaria (PAM) poses a significant risk 
to not only the mother but also to the newborn and is a common cause of adverse pregnancy and birth outcomes, 
including maternal anemia, stillbirth, preterm birth, and low birth weight (LBW). Additionally, PAM is estimated 
to result in 75,000–200,000 infant deaths annually2–9.
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The adverse effects of malaria during pregnancy are in part the result of the ability of infected erythrocytes 
(IE) to accumulate in the placenta10, 11. This accumulation of IE in the placenta is facilitated by VAR2CSA, a 
specific variant of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). VAR2CSA is expressed 
on the surface of the IE and binds to the placental chondroitin sulfate A (CSA) on the syncytiotrophoblast12, 13. 
Immunity directed against VAR2CSA develops naturally with successive pregnancies and appears to protect 
against adverse birth outcomes11. Therefore, vaccination against VAR2CSA could be an effective way to reduce 
the effect of adverse outcomes from PAM14–18.
VAR2CSA is a large 350 kDa transmembrane protein consisting of six Duffy binding like (DBL) domains and 
four interdomain (ID) regions (Fig. 1)19, 20. Several domains mediate the binding of IE to the CSA or elicit a host 
immune response15, 17, 21–29, and vaccine development efforts against PAM have been undermined in part because 
of the difficulty of producing a vaccine targeting such a large and diverse protein. However, the N-terminus region 
of VAR2CSA up to the DBL2x domain has been identified as critical to the binding process and able to induce 
antibody response with similar inhibitory capacity as that elicited against full-length VAR2CSA30. Recently, a 
small fragment of VAR2CSA within the N-terminus region, comprising the ID1-DBL2x region plus 93 amino 
acids of the ID2 interdomain region, was identified as the minimal CSA-binding region, and antibodies to this 
region abrogated the adhesion of IE to CSA in vitro31–34. Therefore, the two leading PAM vaccine candidates, 
PlacMalVac and PriMalVac, each use a single recombinant protein that target overlapping constructs of this 
region (Fig. 1) but contain haplotypes from different parasite strains, either from strain FCR3 (PlacMalVac) or 
from strain 3D7 (PriMalVac)35, 36.
In the past, monovalent malaria vaccines have inadequately accounted for standing parasite antigen diversity, 
resulting in suboptimal efficacy and effectiveness, and a similar phenomenon has been observed in vitro with 
VAR2CSA-based candidate vaccines37–40. Therefore, a VAR2CSA-based vaccine against PAM may need to protect 
against many VAR2CSA strains to be effective. Currently, there is a paucity of data on the genetic diversity of 
ID1-DBL2x in field isolates; most prior genetic studies on VAR2CSA have either genotyped laboratory reference 
strains or only small gene fragments21, 22, 31, 41–44. A better understanding on the genetics and epidemiology of 
ID1-DBL2x antigenic diversity could inform vaccine development efforts.
The aim of this study was two-fold: 1) to investigate the natural antigenic diversity of the ID1-DBL2x region 
of VAR2CSA and 2) to investigate the association between clades of the ID1-DBL2x region of VAR2CSA and 
adverse birth outcomes. Because the sequence and structural diversity of non-VAR2CSA var genes medi-
ates severe malaria syndromes including cerebral malaria we hypothesized that VAR2CSA sequence diversity 
would mediate the severity of placental malaria45. Using a new long-read next-generation amplicon sequencing 
approach, we characterized a 1.6 kb region of ID1-DBL2x and assessed diversity among P. falciparum infected 
placental isolates from two previously completed studies in Malawi (n = 56) and Benin (n = 45) (Fig. 2). We then 
used phylogenetic methods to determine how different strains divided into clades. Lastly, we estimated the asso-
ciation of specific clades on birth weight, low birth weight (LBW), and small for gestational age (SGA), controlling 
for confounders using inverse probability weights. We found a high diversity of VAR2CSA within and between 
countries, but all parasites fell into one of five clades. Infection with parasites from different clades was associated 
with different risk of adverse infant outcomes.
Results
Participant Characteristics. We successfully amplified the 1.6 kb ID1-DBL2x region of var2csa in 101 of 
the available P. falciparum infected placental samples – 56/281 (19.9%) from Malawi and 45/126 (35.7%) from 
Benin, constituting the analytic population. Differences in amplification efficiency between study sites likely rep-
resent different sample types and sample storage. Among the available P. falciparum positive specimens, there 
were no significant differences in demographic characteristics between women whose samples amplified success-
fully and those whose samples did not amplify (Table S3). Demographic and clinical characteristics of the analytic 
population are shown in Table 1. Between countries, there were significant differences in maternal age (mean 
(standard deviation [SD]) 20.5 years [4.6] in Malawi versus 24 years [6.3] in Benin; p value = 0.013) and gesta-
tional age at delivery (mean [SD] 37.1 weeks [3.4] in Malawi versus 39.2 weeks [1.6] in Benin; p value < 0.001). 
Figure 1. Schematic representation of the var2csa gene. VAR2CSA consists of an N-terminal segment (NTS), 
six Duffy Binding Like Domains (DBL), four cysteine-rich interdomain regions (ID), a transmembrane domain 
(TM), and an intra-cellular acidic terminal segment (ATS). Current vaccine development efforts (PlacMalVac 
and PriMalVac) are targeting the NTS-DBL2x region. The ID1-DBL2x region has recently been identified as 
the minimal CSA-binding region that contains major protective epitopes and elicits a strong host immune 
response15, 21–29.
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There were also a significantly higher proportion of primiparous women in Malawi than Benin (51.8% versus 
22.2%; p value = 0.004). The mean [SD] infant birthweight was similar in Malawi: (2677.7 g [539.6 g]) and Benin 
(2840 g [379.7 g]) (p value = 0.146). The prevalence of LBW was 19.6% (n = 11) in Malawi and 13.3% (n = 6) in 
Benin and prevalence of SGA was 16.1% (n = 9) in Malawi and 24.4% (n = 11) in Benin. There were no significant 
differences in the adverse birth outcomes, LBW or SGA by country (Table 1)
Validation of Amplification and Deep Sequencing. To ensure our PCR assay and clustering algo-
rithm were valid, seven reference parasite lines mixed in five pools at varying frequencies were subjected to the 
amplification and analyses pipeline. In each of the five distinct multiclonal template mixtures, we accurately 
detected each of the seven parasite genomic lines (Figure S2). Additionally, we detected parasite haplotypes that 
were included in as little as 5% of the mixed template. Quantitatively, the observed frequencies of each para-
site haplotype correlated well with the expected frequencies (R2 = 0.82) (Figure S3). The clustering of variants 
using the k-mer algorithm produced similar results as expected based on mixtures and highly similar to the 
reference-guided clustering. Some of the variation from the expected is likely due to inaccuracies of DNA quanti-
fication in the preparation of the mixing based on variation in DNA quantification methods (See Supplementary 
Information).
ID1-DBL2x deep-sequencing among clinical isolates. The 101 clinical P. falciparum placental parasite-
mias were sequenced on 14 PacBio SMRT cells and collectively yielded a total 523,482 CCS reads. After extracting 
reads by barcoded primer sequences and filtering based on size and quality requirements, 256,377 (48.98%) reads 
were input into k-mer clustering to identify unique variants in our study population (Figure S4). The median 
Figure 2. Study sites in (A) Malawi and (B) Benin. The map was created with RStudio, version 0.98.1083, 
https://www.rstudio.com/.
Malawi (n = 56) Benin (n = 45) p value
Maternal Age (mean, (SD)) 20.5 (4.6) 24.0 (6.3) 0.013
Gestational Age (mean, (SD)) 37.1 (3.4) 39.2 (1.6) <0.001
Parity (n, (%))
 Primiparous 29 (51.8) 10 (22.2) 0.004
 Multiparous 27 (48.2) 35 (77.8)
Birthweight (mean, (SD)) 2677.7 (539.6) 2840 (379.7) 0.146
Low birthweight (LBW), n(%) 11 (19.6) 6 (13.3) 0.459
Small-for-Gestational-Age (SGA), n(%) 9 (16.1) 11 (24.4) 0.535
Table 1. Demographic and clinical characteristics of the analytic population.
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sequence length from the extracted reads was 1594 bp (range: 1400–1700bp). The median coverage from CCS 
was 1795 reads per sample (range: 16–9241). Overall, k-mer clustering identified 152 unique ID1-DBL2x vari-
ants: 95 in Malawi and 57 in Benin. Of these 152 variants, 17 were observed in more than one woman, and only 
one variant was shared between Malawi and Benin. The mean number of ID1-DBL2x variants per women was 
1.88 (range: 1–7) in Malawi and 1.56 (range: 1–4) in Benin. Overall the ID1-DBL2x fragment showed significant 
genetic variation, with ~30% of the nucleotide positions being polymorphic (Table S4).
The within-population diversity of ID1-DBL2x at the two study sites was assessed by rarefaction, which com-
pensates for the difference in depth of sampling (Fig. 3). The two curves overlap for most of the sampled region 
but only the extrapolated curve for Malawi approaches its asymptote, suggesting that ID1-DBL2x is more diverse 
in Benin as compared to Malawi. This finding is supported by other diversity ecologic metrics (Table S5) and by 
He at the amino acid level, where the ID1 region in Benin is more diverse than in Malawi (Figure S5). Between 
populations, Wright’s Fixation index (FST) was estimated with a sliding window over the entire 1.6 kb region for 
pairwise comparison between countries, women with differing gravidities, and the two vaccine clades (3D7 and 
FCR3). Both the FST values comparing variants from women with differing gravidities and the values between 
countries approached zero (FST range: 0–0.11), indicating high degree of genetic similarity However, comparing 
FST values between 3D7 and FCR3 clade, overall the two clades look similar except for a ~100 bp region where the 
two populations differ significantly (FST = 0.26–1.0) (Figure S6). Assessment of Tajima’s D, a signature of balanc-
ing selection, shows similar evidence of immune selection across populations but with differences in the domains 
under selection (Table S4 and Figure S7).
Phylogenetic clustering. The maximum-likelihood phylogenetic trees clustered the observed variants from 
Malawi into two distinct clades, with the clustering supported by branch-point bootstrap values > 80%. The two 
clades co-clustered with the two referent strains which were used to design the current vaccines (3D7 or FCR3) 
(Fig. 4A). In Malawi, 21 (37.5%) and 22 (39.3%) women were infected with only 3D7-like and FCR3-like variants, 
respectively (Table 2). Variants from both clades were detected in 13 (23.2%) women. In contrast, the phyloge-
netic trees in Benin clustered the variants into five significantly distinct clades (bootstrap values > 80%). In addi-
tion to the 3D7 and FCR3 clades identified in Malawi, three clades unique to Benin were detected (Fig. 4B). While 
3D7-like variants only infected 4 women (8.9%) and FCR3-like variants infected 13 (28.9%), 17 women (37.8%) 
were infected with a variant from one of the three clades unique to Benin. We also observed 6 (13.3%) women 
infected with both 3D7-like and FCR3-like variants, 4 (8.9%) women were infected with FCR3-like variants and 
variants from the three Benin unique clades, and one (2.2%) woman who was infected with variants from the 
two vaccine clades as well as the other clades (Table 2). The PCoA analyses showed that out of the non-vaccine 
clades, clades 4 and 5 appear to be closely related to the 3D7-like clade. Interestingly, variants in clade 3 displayed 
a genetic background resembling both 3D7-like and FCR3-like clades, indicating a possible recombination event 
(Figure S8).
Associations with birthweight. The median (IQR) infant birthweight among mothers in Malawi infected 
with only 3D7-like variants was 2450 g (2150 g–2850 g) whereas mothers infected with only FCR3-like variants 
had a median birthweight of 2800 g (2600 g–2960 g). In Benin, the median (IQR) infant birthweight of mothers 
infected with only 3D7-like variants was 2710 g (2490 g–2825 g) and 2720 g (2580 g–3250 g) for those women 
infected with only FCR3-like variants (Table 2).
In both crude and adjusted regression models, compared to mothers infected with variants only from the 
FCR3-like clade, mothers infected with variants from only 3D7-like clade delivered babies with lower infant 
Figure 3. Rarefaction curves of ID1-DBL2x variants in Malawi (blue) and Benin (red). Calculated rarefaction 
curves are represented by solid lines. Extrapolated curves are depicted by dotted lines. The rarefaction curves 
were bootstrapped 1000 times to generate the 95% confidence intervals (CIs), which are represented by lightly 
shaded red and blue.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 7768  | DOI:10.1038/s41598-017-04737-y
birthweight (adjusted difference: −267.99 g; 95% CI: −466.43 g, −69.55 g) (Table 3). This reduction in infant 
birthweight was present when each country was analyzed alone: In Malawi, placental infection with 3D7-like 
variants was associated with a reduction in infant birthweight of 330.97 g (95% CI: −628.44 g, −33.49) and in 
Benin by 147.88 g (95% CI: −530.06, 234 g) after controlling for parity (Table 3), but the latter confidence intervals 
included 0.
In Benin, women infected with variants from clades other than the vaccine clades delivered babies with 
increased infant birthweight (185.63 g; 95% CI: −67.80, 439.06 g) as compared to women infected with only 
FCR3-like variants. Similarly, women co-infected with both 3D7-like and FCR3-like variants delivered babies 
with increases in infant birthweight across all populations (Table 3). However, women infected with variants from 
both vaccine and non-vaccine clades reported significantly lower infant birthweight across both countries (range: 
−280g – −133.41 g) (Table 3).
Association with small-for-gestational-age (SGA) and low birth weight (LBW). Given the sparse 
distribution of categorical adverse birth outcomes SGA and LBW in our study population (Table 2), we modeled 
the effect of only the vaccine clades (3D7-like and FCR3-like) on SGA and LBW. Compared to women infected 
Figure 4. Maximum-likelihood phylogenetic trees of ID1-DBL2x variants in (A) Malawi and (B) Benin. All 
trees were bootstrapped 1000x and bootstrap values >80 were used as cutoff points for significant branch 
differentiation. In Malawi, variants clustered in two distinct clades with the two referent strains (3D7 and 
FCR3). In Benin, in addition to the 3D7 and FCR3 clades, three other clades were detected.
Clades
Malawi Benin
N SGA (%) LBW (%)
Birthweight 
(median (IQR)) N SGA (%) LBW (%)
Birthweight 
(median (IQR))
3D7 21 6 (28.1) 10 (47.6) 2450 (2150–2850) 4 2 (50.0) 1 (25.0) 2710 (2490–2825)
FCR3 22 2 (9.1) 1 (4.6) 2800 (2600–2960) 13 3 (23.1) 2 (15.4) 2720 (2580–3250)
3D7 + FCR3 13 1 (7.7) 2850 (2700–3000) 6 2 (33.3) 1 (16.7) 2900 (2550–3200)
Other 17 3 (17.6) 1 (5.9) 3100 (2790–3160)
FCR3 + Other 4 1 (25.0) 2550 (2365–2610)
3D7 + FCR3 + Other 1 1 (100) 2700
Table 2. Distribution of infant birth weight and adverse birth outcomes by ID1-DBL2x clades in Malawi and 
Benin.
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with only FCR3-like variants, the unadjusted prevalence of LBW was higher in women with only 3D7-like vari-
ants in Malawi (47.6% versus 4.6%) and in Benin (25% versus 15.4%) (Table 2). Phylogenetically, while there were 
a few LBW variants clustered in the FCR3-like clade, the majority of the LBW variants in Malawi were present 
in the 3D7-like clade (Fig. 5A). In Benin, distribution of LBW variants was more evenly distributed between 
3D7-like and FCR3-like clade (Fig. 5B). In a pooled analysis adjusted for parity and country, compared with 
women infected only with FCR3-like variants, those infected with only 3D7-like variants had higher odds of LBW 
(OR: 5.41; 95% CI: 0.99, 29.52).
Similarly, the unadjusted prevalence of SGA was higher among women infected with only 3D7-like variants 
than women infected with only FCR3-like variants in Malawi (28.1% versus 9.1%) and in Benin (50% versus 
23.1%) (Table 2). As observed with LBW, in pooled analysis, compared to women infected with only FCR3-like 
variants, women infected with only 3D7-like variants had higher odds of delivering a SGA infant after controlling 
for parity and country (OR 3.65; 95% CI 1.01–13.38) (Table S6). When stratifying by country, though not sta-
tistically significant, women infected with only 3D7-like variants had higher odds of delivering a SGA infant in 
Malawi (OR: 5.21; 95% CI: 0.77–35.41) and in Benin (OR: 2.98; 95% CI: 0.27–32.48) (Table S6).
Discussion
A VAR2CSA-based vaccine against PAM will be the first syndrome-specific malaria vaccine and may substantially 
reduce one the major causes of adverse delivery outcomes in malaria-endemic sub-Saharan Africa. The current 
vaccine candidates targeting the N-terminus region of VAR2CSA are monovalent vaccines. Our study shows 
that the ID1-DBL2x epitope in the N-terminus region is highly diverse among P. falciparum-infected pregnant 
women in Malawi and Benin. There were 152 variants found among 101 women, and they clustered phyloge-
netically into five distinct clades. There was more genetic diversity in Benin than Malawi with sequence-based 
evidence of prior immune selection in both populations. Furthermore, variants from the 3D7-like clade were 
associated with adverse birth outcomes including newborns with lower birthweight. Taken together, the intrinsic 
diversity of this VAR2CSA region along with the association of a specific P. falciparum genotype with more severe 
clinical consequences suggest that an effective VAR2CSA-based vaccine aimed to prevent placental malaria and 
its sequelae will require multivalent activity.
The high degree of genetic diversity of var2csa observed in our study population is concordant with previously 
reported overall species richness of var genes46. In Malawi and Benin, among the 152 variants, only 17 were found 
in more than one woman and a single haplotype was shared between the two countries. Rarefaction curves show 
that the population in Benin, which contained all five clades, is more diverse than the population in Malawi, 
which only contained the 3D7-like and FCR3-like clades. Multiple ecological indices corroborate this difference 
in haplotype richness between sites. Several reasons may explain this higher diversity, including that transmission 
of malaria is higher in Benin. The high levels of diversity has important implications for future vaccine design. 
Taking the relevant genetic diversity into account when designing a vaccine will be critical in producing a candi-
date that has excellent cross-protective effect.
The primary driver for differentiation between clades was a 100 bp region that separated 3D7-like and 
FCR3-like parasites. This is seen by the high FST in the 100 bp region, and relatively low FST across the rest of the 
gene (Figure S6). Interestingly, all parasites, including those in the 3 clades unique to Benin, contained either a 
3D7-like or FCR3-like domain. The branching off of these 3 additional clades were primary driven by differences 
in the ID1 region. This is consistent with our previous observation of an ID1 sequence of var2csa which appears 
to be unique to Benin47. Furthermore, some of the Beninese variants had large insertions in this domain.
Birthweight
Crude Adjusted*
Effect** 95% CI Effect** 95% CI
Pooled
FCR3 REF — — REF — —
3D7 −251.49 −474.28 −28.69 −267.99 −466.43 −69.55
3D7 + FCR3 99.55 −151.45 350.56 22.36 −199.23 243.94
Malawi
FCR3 REF — — REF — —
3D7 −262.24 −557.46 33.00 −330.97 −628.44 −33.49
3D7 + FCR3 151.76 −204.90 508.43 100.75 −260.62 462.12
Benin
FCR3 REF — — REF — —
3D7 −153.41 −548.08 241.26 −147.66 −530.06 234.75
3D7 + FCR3 14.10 −328.97 357.15 21.99 −310.39 354.39
Other† 187.33 −74.23 448.89 185.63 −67.80 439.06
FCR3 + other† −323.41 −718.08 71.26 −280.21 −662.62 102.19
3D7 + FCR3 + other† −110.91 −816.91 595.09 −133.24 −906.49 640.02
Table 3. Associations between ID1-DBL2x clades and infant birthweight (grams). *Adjusted for country 
(pooled analysis only) and parity using inverse probability weights (IPW). **Change in infant birth weight 
(grams). †Other clade includes variants from clades identified only in Benin.
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Fortunately, our data also suggest that a ID1-DBL2x vaccine that is broadly effective in one country has a good 
chance to be successful in multiple countries. Between countries, there was almost no genetic differentiation 
detected by FST across the entire ID1-DBL2x region. Variants in the two countries were also more similar based on 
amino acid sequence than nucleotide sequence (Figure S5). This pattern of high overall nucleotide diversity, but a 
similar amino acid content has been described previously between Malawi and The Gambia for the antigen in the 
RTS,S vaccine, which showed similar efficacy in Malawi and West Africa48. Surprisingly, there was little genetic 
difference between primi-, secundi-, and multigravid women in terms of complexity of infection and the presence 
or absence of specific variants. We know that multigravidae develop immunity to VAR2CSA; these results suggest 
that the immunity may not be strain specific.
Importantly, we observed an association between specific P. falciparum clade and worsened birth outcomes. 
Overall, the 3D7-like clade was associated with adverse birth outcomes. Compared to women infected with only 
FCR3-like variants, women infected with variants only from 3D7-like clade delivered babies with reductions in 
birthweight between 147.7 g to 331.0 g in both Malawi and Benin, respectively (Table 3). This reduction in birth 
weight is clinically significant and comparable to the reduction in birth weight observed due to active mater-
nal smoking – approximately a 200 g deficit49. Women infected with variants from only 3D7-like clade also had 
Figure 5. Maximum-likelihood phylogenetic trees of ID1-DBL2x variants by low birth weight (LBW) and 
small-for-gestational age (SGA). Panel A and C show data for Malawi for LBW and SGA, respectively. Panels 
B and D show data for Benin for LBW and SGA, respectively. All trees were bootstrapped 1000x and bootstrap 
values >80 were used as cutoff points for significant branch differentiation. LBW was defined according to 
World Health Organization’s criteria as infant with a birth weight of less than 2500 grams. 3D7 (green) and 
FCR3 (purple) were detected in both countries. Majority of the LBW variants (red) in Malawi were present 
in the 3D7-like clade (green) whereas in Benin, the LBW variants were more evenly distributed between 
3D7-like (green) and FCR3-like (purple) clades. SGA was defined as infant with a birth weight below the 10th 
percentile for babies of the same gestational age at delivery. 3D7 (green) and FCR3 (purple) were detected in 
both countries. SGA variants (red) clustered more readily in 3D7-like clade in Malawi whereas in Benin, the 
distribution was more even between 3D7-like and FCR3-like clades. We also identified four SGA variants 
clustered in clade 3.
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higher odds of delivering a LBW and SGA infant. Even though we used FCR3-like clade as a referent group to 
estimate relative pathogenicity, we observed that LBW and SGA variants indeed clustered in FCR3-like clade in 
both Malawi and Benin. The magnitude of the association between infection from 3D7-like variant and poor out-
come was greater in Malawi than Benin. This could have been due to the fact that Benin experiences higher levels 
of malaria transmission than Malawi; pregnant women in Benin might have had greater pre-existing immunity 
than pregnant women in Malawi and this immunity could have mitigated strain-dependent pathogenicity.
Despite this association, adverse events were found within other clades. This suggests, that while a 3D7-like 
vaccine might be a preferable monovalent vaccine, a polyvalent or strain transcendent vaccine that protects 
against multiple clades would be more efficacious. While in vivo evidence of the strain specificity of immunity to 
this region of VAR2CSA is limited, there is some supportive evidence for its role. First, in vitro studies show a sub-
optimal cross-protective effect (between 3D7 and FCR3 clades) based on in vitro blocking assays37, 41. Second, we 
show that while overall the gene exhibits a strong genetic signature of immune selection based on Tajima’s D val-
ues of >1 (Table S3), the domains of elevated Tajima’s D vary across clade (Figure S7). This is similar to the genetic 
signal that has been seen at orthologous antigens between malaria species which are known to interact differently 
with host immunity50. Both of these lines of evidence suggest that the interaction with the host immune system is 
different between the clades and that immune selection is likely the primary driver for the diversity of the antigen.
Previous studies have relied on Sanger sequencing or cloning, both of which limit depth and sensitivity, or 
on breaking up the fragment into smaller fragments to deep-sequence and reassembling haplotypes in silico, a 
method which may complicate haplotype reconstruction21, 22, 31, 41–44. The PacBio CCS platform allowed us to 
sequence a long fragment of var2csa at great depth without requiring assembly of haplotypes. Additionally, bar-
coding individual samples allowed us to link variants detected through deep-sequencing to individual women 
and their clinical and demographic data. Due to the high rates of polymorphism, polyA repeats, and PacBio error 
rate, variant calling through conventional software was not adequate. As a result, we implemented a k-mer clus-
tering algorithm which provided a more appropriate way to determine unique variants of var2csa.
Our study was limited by the number of P. falciparum infected placental samples we were able to include in 
our analyses. This was in part due to low yield in amplifying ID1-DBL2x, a long hypervariable region of var2csa 
from DNA extracted from dried blood spots in Malawi. The generalizability of our results is also limited as we 
had access to samples from only two countries in Africa. However, the results from our study agree with other 
studies that were able to deep-sequence smaller fragments of var2csa from multiple countries in Africa as well as 
from Asia and South America31. We also had sparse distribution of our categorical adverse birth outcomes that 
precluded us from detecting significant associations. However, including birth weight as a continuous outcome 
and controlling for confounders using inverse probability weights increased our ability estimate effect of vaccine 
clades on infant birth weight. Given that gestational age at delivery is a strong predictor of infant birth weight and 
is itself affected by malaria exposure during pregnancy, gestational age at delivery may be a mediator on the causal 
pathway of ID1-DBL2x clade and birth weight. We were therefore, limited in our ability to estimate the direct 
effect of ID1-DBL2x clade on birth weight. We were able to only estimate the total effect of ID1-DBL2x clade on 
birth weight, including the effect of gestational age on birth weight. This limited our ability to draw inferences on 
the effect of ID1-DBL2x clades on fetal growth specifically.
This is the first study investigating effects of specific genetic variants of var2csa on clinical outcomes. We 
employed an integrative approach, using molecular epidemiology, next-generation sequencing, and population 
genetics to examine the antigenic diversity of var2csa, identify immunologically relevant selection pressures, 
understand the genetic relatedness between populations, and identify ID1-DBL2x clades with differential patho-
genicity. Previous attempts to develop a general vaccine against malaria have not taken parasite antigenic diversity 
into account; this is one possible explanation for suboptimal efficacy and effectiveness38, 40. The results from our 
study provide strong support for the development of polyvalent VAR2CSA-based vaccines against PAM. As clini-
cal trials get underway for testing vaccines against PAM, characterizing genetic diversity and monitoring parasite 
populations will help explain changes that affect vaccine efficacy and inform future vaccine improvement and 
development efforts.
Methods
Study population and sample collection. Clinical samples from two previously completed studies 
in Malawi and Benin were used (Fig. 2). In Malawi, dried blood spot (DBS) samples of placental blood were 
obtained from a randomized controlled trial conducted between 2010 and 2013, which aimed to assess the effi-
cacy of intermittent screening and treatment in pregnancy (ISTp) with Dihydroartemisinin-Piperaquine (DP)51. 
In Benin, packed red blood cell (pRBC) samples of placental blood were acquired from a prospective cohort study 
conducted between 2008 and 2010 to quantify the effects of PAM and investigate immunological responses to 
malaria infection during pregnancy52. All samples included in these analyses were placental blood specimens, 
collected at delivery from P. falciparum-infected pregnant women as determined by microscopy or RDTs and 
later tested by PCR targeting the P. falciparum lactate dehydrogenase (pfLDH) gene. At delivery, demographic 
and clinical data were collected on mothers and new-borns. Information regarding reproductive history, current 
pregnancy, and infant health was also collected. Additional details of the studies have been published elsewhere 
and is summarized in Supplementary Information.
Women in both studies were enrolled after obtaining signed informed consent. The current and parent studies 
were approved by institutional review boards at Institut de recherche pour le développement in France, Science 
and Health Faculty (University of Abomey Calavi) in Benin, Liverpool School of Tropical Medicine, Malawian 
National Health Science Research Committee, and University of North Carolina at Chapel Hill. All methods were 
carried out in accordance with the approved guidelines and regulations.
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Amplification of the ID1-DBL2x Domain. For Malawi specimens, genomic DNA (gDNA) was extracted 
from dried blood spots using 20% Chelex-100 (Bio-Rad, Richmond, CA) as previously described53. For Benin 
specimens, gDNA was extracted from RBC pellets using Thermo Scientific GeneJET DNA extraction kit (Thermo 
Fisher, Waltham, MA) as recommended by the manufacturer. From all gDNA, we then amplified the target region 
in technical duplicates using a hemi-nested PCR amplification strategy that used barcoded forward and reverse 
primers specific to each patient and technical replicate (Table S2). To inform primer design we used all publically 
available var2csa reference sequences to guide primer placement. Details about primer design and PCR condi-
tions are provided in the Supplementary Information.
Amplicon deep sequencing. Concentrations of successful PCR amplifications were quantified using 
the Genomic DNA ScreenTape assay on the Agilent 2200 TapeStation system. PCR products were then pooled 
together based on barcode compatibility. Each pool was gel extracted and purified using Qiagen gel extrac-
tion kit (Qiagen, Carlsbad, CA) per manufacturer’s protocol, quantified by Tapestation, and submitted for 
deep-sequencing on the PacBio circular consensus sequencing (CCS) platform using the P5-C4 chemistry at the 
UNC Highthrouput Sequencing Facility.
Generation of ID1-DBL2x Haplotypes. Raw sequences were cleaned and clustered using a novel cluster-
ing algorithm based on k-mer distances54. The end result of k-mer clustering yielded one or more phased consen-
sus sequences for each woman present in the study population. Haplotypes from technical PCR duplicates from 
each patient sample were only accepted when they appeared in both replicates. The haplotype frequencies were 
calculated as the average of the frequencies in the two replicates. All variants were initially aligned in MEGA6 
using MUSCLE alignment55. Due to a large number of insertions and deletions and polyA repeats, we manually 
curated the alignment to improve the alignment output from MEGA6. Details of the clustering method are pro-
vided in the Supplementary Information and Supplementary Figure S1. All sequences have been submitted to 
GenBank (GenBank accession numbers: MF061812-MF061963).
Validation of Haplotype Determination. We conducted a validation study using pools of reference 
genomic parasite lines to ensure that our assay and clustering algorithm were appropriate and accurate. We mixed 
seven reference parasite lines (3D7, FCR3, 7G8, DD2, K1, RO33, and V1/S) from BEI resources (formerly known 
as MR4, Manassas, VA) in varying frequencies (1–50%) in five pools and subjected them to the above amplifica-
tion and analyses pipeline. Details of mixture generation are in the Supplementary Information. We estimated the 
component parasite lines for each pool and their relative frequency. We then compared the “expected” results to 
de novo clustering and reference-guided clustering (determined by aligning individual sequencing reads to the 
known reference sequence for each strain ascertained by primer walking and Sanger sequencing done at Eton 
Biosciences, RTP, NC) to determine “observed” haplotype frequencies.
Within population diversity, between population diversity and phylogenetics of 
ID1-DBL2x. To better characterize the natural diversity of ID1-DBL2x, we assessed population diversity and 
the phylogenetics in order to assess the extent of antigen diversity, for sharing of haplotypes between sites, and for 
clustering of haplotypes into clades. A brief summary of approaches is provided here with additional details in the 
Supplementary Information. Measurements of within population (alpha) diversity were calculated in EstimateS56 
and R using the adegenet and pegas packages57, 58. We determined bootstrapped rarefaction curves for each pop-
ulation, as well as heterozygosity (He), Shannon index (H’), abundance coverage estimator (ACE), incidence 
coverage estimator (ICE), and Chao richness estimators59–63. We then compared these measures between the two 
countries and between women of different gravidity. Statistically significant differences in alpha diversity metrics 
between different groups were tested using Kruskal–Wallis test. An α of 0.05 was determined a priori to test for 
significant differences.
To characterize between population (beta) diversity, we assessed Wright’s fixation index (FST) and performed 
a principal coordinate analysis (PCoA) to assess the genetic relatedness64. We calculated nucleotide diversity (π) 
and Tajima’s D test65 for the entire ID1-DBL2x region as well as with a sliding window approach to assess localized 
selection pressures acting upon vaccine target66. Tajima’s D was calculated on ID1-DBL2x variant populations 
by country and major clades. Differences were assessed between Malawi and Benin as well as between the dif-
ferent clades identified by phylogenetic analysis. All measures of genetic relatedness and selection (FST, PCoA, π, 
Tajima’s D) were calculated in R using the adegenet57 and PopGenome67 packages.
Phylogenetic trees were generated in MEGA6 using the maximum composite likelihood method where 
genetic distances were calculated through the Tamura-Nei model68. The phylogenetic trees were bootstrapped 
1000 times to compute branch support and provide precision in the clustering detected. Bootstrap values of 
greater than 80% were used as cutoff point to identify significant distinct clades. All phylogenetic trees were vis-
ualized using the APE package for R69.
Associations of VAR2CSA clade with delivery outcomes. We examined associations between clades 
and birth outcomes to identify pathogenic clades. Outcomes of interest were infant birth weight, LBW, and SGA. 
At delivery, infant birth weight was recorded to the nearest gram within 24 hours using a calibrated digital scale. 
LBW was defined as a birth weight of less than 2500 grams70. SGA was defined as an infant with a birth weight 
below the 10th percentile for babies of the same gestational age at delivery71.
Associations were determined by first examining if there was any clustering of LBW and SGA by clades in 
the MLE phylogenetic trees. Pregnant women were categorized based on the respective clade in which the var-
iants detected from their samples clustered. We then used linear and logistic regression to estimate the effect of 
clades on birth weight, LBW, and SGA, respectively. We controlled for potential confounders and standardized 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7: 7768  | DOI:10.1038/s41598-017-04737-y
the groups defined by clades to the marginal distribution of potential confounders in the study population using 
inverse probability weights. The denominator of the weights for the different clades of ID1-DBL2x was estimated 
using polytomous logistic regression, conditional on parity. For the pooled analyses, we also included country 
in estimating the denominator of the weights. Weights were stabilized using the marginal distribution of the 
ID1-DBL2x clades in our study population. We estimated differences in birth weight and relative odds of LBW 
and SGA associated with infection with each clade, using FCR3 as the referent category. All analyses were con-
ducted using SAS version 9.3 (SAS Institute, Cary, North Carolina).
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